Drugs / ABL103
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06126666 | Nov 2023 → Dec 2025 overdue | neoplasm | ABL Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07158918 | Aug 2025 → Dec 2027 expected | cancer | ABL Bio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABL103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126666 ↗ |
| Route | Intravenous | “IV infusion” NCT07158918 ↗ |